Medical cannabis has been used in treatments for 3,000 years by various cultures and in various ways. Historical evidence suggests that ancient physicians around the world mixed cannabis into medicines to treat pain and other ailments.
Today, cannabis finds scope in a wide range of medical conditions, with its medicinal use mainly associated with the relief of physical and mental ailments, as well as keeping the body in balance.
Medical cannabis is used, among other things, in the treatment of seizures in children and adults, reduces spasticity in patients with multiple sclerosis, is indicated in the prevention and treatment of nausea and/or indirect nausea due to chemotherapy, in the treatment of anorexia and in the weight loss of patients with Epictetus syndrome Immune Deficiency (AIDS). According to scientific studies, it can contribute to the treatment of chronic neuropathic pain and to the relief of patients in the final stages of cancer and many other diseases.
In 2017, the use of medicinal cannabis was legalized in Greece and in March 2018, its cultivation, processing, marketing and export. Today, the production of finished medicinal cannabis products with a tetra-hydrocannabinol (tetra-hydrocannabinol, THC) content of more than 0.2% is allowed, with the aim of making them available for purely medical purposes either domestically or for export. The process of action of preparations containing cannabinoids is based on the functioning of the Endocannabinoid System (ECS).
Tikun Olam is a pioneering company and global leader in medicinal cannabis research. Aligned with Israel’s legal framework, our team of scientists has been conducting cannabis research and clinical studies for over a decade, achieving outstanding results and amassing one of the largest cannabis treatment databases in the world with over 30,000 patients.
Through extensive research and development, Tikun’s proprietary strains have been genetically optimized and clinically proven to provide symptomatic relief for a wide variety of conditions including Crohn’s disease, Parkinson’s disease, autism, cancer, inflammatory disease of the intestine and others.
Clinical successes have encouraged Tikun to devote more resources to further improving the safety and efficacy of its products, as well as understanding the healing properties of the cannabis plant. Tikun continuously conducts laboratory studies (both in vitro and in vivo), retrospective analyses, and clinical trials, and works diligently to monitor patients.
Read Tikun’s Research
It is a complex network of receptors, signaling molecules (endocannabinoids) and enzymes. The discovery of the ECS took place relatively recently. Although the molecules of THC and CBD (phytocannabinoids) had already been isolated in the 60s and their structure had been elucidated by Dr. Raphael Mechoulam, the mechanism through which these molecules exerted their action remained unknown. Until 1988, it was found that the brain of mammals has receptors that respond to components of cannabis. A few years later, the CB1 and CB2 receptors of the ECS were cloned, while in 1992 it was isolated for the first time, again by the laboratory of Dr. Mechoulam, the endocannabinoid molecule anandamide. The findings of Dr. Mechoulam were the starting point for scientific research and clinical studies on the therapeutic uses of the cannabis plant and were the reason for the establishment of Tikun Olam in 2002.
With regard to the role of the ECS, a wealth of research shows that it plays an important role in human health and well-being. It serves the essential function of restoring homeostasis through physiological and regulatory mechanisms. Its effectiveness is enhanced by the uptake of cannabinoids and their binding to ECS receptors. The beneficial effect of cannabinoids is supported by a large number of literature references. Cannabinoids potentially help relieve pain, manage stress, improve mood, increase appetite and energy. In addition, they help reduce nausea and strengthen the immune system.
Tikun Olam Europe’s signature medical cannabis is cultivated using exclusively high-level scientific techniques. It features the exclusive use of cannabis strains that have been genetically modified for maximum effectiveness in symptomatic relief. Especially for the development of its pharmaceutical formulations, Tikun Olam Europe has selected from a range of cannabis strains of Tikun Olam Israel, those covering the widest range of medical cases, for which there is a proven effectiveness, based on clinical studies.
